Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis

Open access
Chesney, Edward, Oliver, Dominic, McGuire, Philip · 2022 · Psychopharmacology

Abstract

The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available. For those with first-episode psychosis, all licensed antipsychotic medications act via dopamine D 2 receptors. While treatment with antipsychotics is transformative in some patients, in others, it is ineffective. In addition, these medications can often cause adverse effects which make patients reluctant to take them. This is a particular problem in the early phases of psychosis, when patients are being treated for the first time, as unpleasant experiences may colour their future attitude towards treatment. Recent research has suggested that cannabidiol (CBD), a compound found in the Cannabis sativa plant, may have antipsychotic effects and relatively few adverse effects and could therefore be an ideal treatment for the early phases of psychosis, when minimising adverse effects is a clinical priority. In this review, we consider CBD’s potential as a treatment in the clinical high risk and first-episode stages of psychosis. First, we describe the limitations of existing treatments at these two stages. We then describe what is known of CBD’s mechanisms of action, effectiveness as a treatment for psychosis, adverse effects and acceptability to patients. We discuss how some of the outstanding issues about the utility of CBD in the early phases of psychosis may be resolved through ongoing clinical trials. Finally, we consider the impact of recreational cannabis use and over-the-counter cannabinoids preparations and discuss the potential therapeutic role of other compounds that modulate the endocannabinoid system in psychosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-021-05905-9

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 93 references

Research works printed but not linked: 3

  1. Gibbs B, Yates DA, Liebling J (2019) CBD in the UK. Centre for Medicinal Cannabis, London
  2. Morrison P, Taylor DM, Mcguire P (2019) The Maudsley guidelines on advanced prescribing in psychosis. John Wiley & Sons
  3. Taylor DM, Barnes TRE, Young AH (2018) The Maudsley prescribing guidelines in psychiatry–eleventh edition. John Wiley & Sons

Cited by

See all 43

Metadata

Authors
Chesney, E., Oliver, D., & McGuire, P.
Affiliations
King's College London (GB)
Corresponding author
Chesney, Edward
Venue
Psychopharmacology
Published
2021-07-13
Volume
239
Issue
5
Pages
1179-1190
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W3179334404
Cited by
40
References
93
Citations by year
2026: 5 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 4 · 2021: 1
FWCI
0.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research (NIHR300273)
  • King's College London (MR/N013700/1)
  • Medical Research Council (MR/N013700/1)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
cannabidiol, early psychosis, clinical high risk for psychosis, first-episode psychosis, antipsychotic drugs, antipsychotic adverse effects, endocannabinoid system, mechanism of action, treatment acceptability, recreational cannabis use, Cannabis sativa
MeSH terms
Cannabidiol, Cannabinoids, Cannabis, Humans, Psychotic Disorders, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. https://app.cochat.ai/papers/10.1007/s00213-021-05905-9
The paper
Chesney, E., Oliver, D., & McGuire, P. (2022). Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology. https://doi.org/10.1007/s00213-021-05905-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.